About Me

01/01/06

Home
About Me
Poker Articles
Poker Sites
Sports Betting

 

My Poker Playing Story

I'm Nsidestrate or just Nside to my friends.  I consider myself a pretty serious poker player.  I primarily play full-ring limit poker at limits up to 30/60.  I still feel a bit excited when I play 30/60, but 15/30 seems like everyday stuff.  I think I'm actually a pretty decent NL tourney player and I'm pretty comfortable with short-handed play too.  I'm still a neophyte at heads-up play and I really don't know what I'm doing at NL ring games.

I started playing on-line at PokerRoom, playing 1/2 with a $500 bankroll.  My lovely bride, Precio clonazepam 2mg mexico, seemed certain that this was going to lead to some kind of disaster or another.  Of course, she thinks everything is going to lead to some sort of disaster or another.  I don't think she was that worried that I would get beat, but she was convinced that they would never give us any more back if we won.  We were quite paranoid and we gave them an obscure credit union account so that they couldn't get to any real money.

I learned the value of bonus right away.  I deposited the $500 into PokerRoom for a $100 bonus.  I eventually won $80 on that bonus chase, but I was up $180 when you counted the bonus.  In those days, I mostly just followed Matthew Hilger's starting hand chart and played a pretty tight post-flop game.  It was quickly obvious that most of my fellow players didn't read the same books I did.

I've gotten a lot smarter since then and I cringe when I watch some of the silly things I used to do in my old hand history files.  I'm not really comfortable yet with talking about specific figures, but I've won a lot more money than I thought was possible.  I'm not sure what is next for me.  I may concentrate on playing some of the bigger tourneys to try to test myself in that field or I may push on up to 50/100 at Party.  I've watched the game a fair amount and it doesn't look that tough to me.

My Personal Story

I'm 42 years old, with a lovely wife who supports me in all my crazy ventures.  We don't have any kids, so we mostly spoil our poker-playing cat and my various nephews.  I'm a geek by trade.  My original love was database design, but I've done a whole lot of software development and I'm currently a fairly senior executive of a large computer consulting firm.

I may be the most private guy ever to have a blog, so that's about it.

Cost of provigil vs adderall | About Me | Buy diet pills with sibutramine | Zolpidem 10 mg ohne rezept kaufen | Over the counter diet pills that are similar to adipex

This site was last updated 01/01/06

Safe site to buy diazepam uk | Buy phentermine uk price | Drugstore 10 discount | Cheap generic adderall xr | Buy modafinil 200mg uk


Adjusting coumadin dose by to determine if the clinical benefit outweighs associated side effects. For all patients in whom a lower dose of coumadin could not adequately control their disease due to the potential for a toxic reaction, they would be given a dose of 2-4 times the normal dose. Patients who were being switched off of anti-coagulant therapy would receive another as a prophylactic measure until they were no longer at risk of an adverse reaction. At this point the patient would then be switched back onto coumadin. Although the study showed improvements in mortality all study groups, some patients, mortality was still significant (15%). The reason for these increases in mortality remains unclear, however, it may be related to additional bleeding. It was also noted that after discontinuance of the anti-coagulant, some patients experienced an increase in blood loss which some cases was substantial would have been reflected in the observed changes risk of mortality. The authors of this study suggested that the risk of mortality would only be lower than that in the placebo groups patients with severe bleeding complications; however, this could be an artefact as the treatment was not effective if severe bleeding was not managed; rather, most of the bleeding complications were treated with oral anticoagulant and no risk of other bleeding complications would occur. While the authors of this study noted significant adverse events, it did not take account of the risk life-threatening bleeding complications. Despite the limitations, this study provides additional evidence supporting the use of a low coumadin dose in patient group experiencing severe bleeding complications, such as acute coronary syndromes or septicaemia. In summary, as a low coumadin dose has been shown to be effective in clinical studies, we feel that a low dose should be continued for a further 6 months,